-+ 0.00%
-+ 0.00%
-+ 0.00%

InflaRx Halts Vilobelimab Phase 3 Trial In Pyoderma Gangrenosum After Futility Finding In Interim Analysis

Benzinga·05/28/2025 06:36:03
Listen to the news

the Independent Data Monitoring Committee (IDMC) conducting the unblinded interim analysis for the Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG), recommended that the trial be stopped due to futility. This recommendation was based on data analysis of the first 30 patients enrolled in the study, with no unexpected adverse events noted by the IDMC. InflaRx as the study sponsor remains blinded to the study results.